Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.62 |
| ▸ | VDR | P11473 | 9/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.61 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8610933 | 1.00 | HDAC6 (0.62) | HDAC6HDAC3VDRHDAC2CDC25A | |
| SCHEMBL8677057 | 0.88 | HDAC6 (0.56) | HDAC6HDAC3VDRHDAC2ADORA3 | |
| SCHEMBL8677059 | 0.88 | HDAC6 (0.56) | HDAC6HDAC3VDRHDAC2ADORA3 | |
| SCHEMBL7570689 | 0.86 | VDR (0.63) | HDAC6HDAC3VDRHDAC2CDC25A | |
| SCHEMBL7570677 | 0.86 | VDR (0.63) | HDAC6HDAC3VDRHDAC2CDC25A | |
| SCHEMBL30452668 | 0.84 | VDR (0.79) | VDRADORA3SLC6A2AGTR1 | |
| SCHEMBL3679281 | 0.83 | VDR (0.83) | VDRADORA3SLC6A2AGTR1 | |
| SCHEMBL13532024 | 0.83 | HDAC6 (0.81) | HDAC6HDAC3VDRHDAC2 | |
| SCHEMBL8971029 | 0.81 | CDC25A (0.54) | HDAC6HDAC3VDRHDAC2CDC25A | |
| SCHEMBL24299437 | 0.79 | NR1I2 (0.63) | HDAC6HDAC3VDRHDAC2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0696275-B1 | VITAMIN D AMIDE DERIVATIVES | RES INST MEDICINE CHEM (US) | 1998-08-12 | — | — | EP | claimed |
| US-7851461-B2 | acetylsalicylic acid, 1,25 dihydroxycholecalcipherol and calcium | COLOTECH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1389122-B1 | PREVENTION OF EPITHELIAL CANCER | COLOTECH AS (DK) | 2009-09-30 | — | — | EP | disclosed |
| US-20040116393-A1 | Prevention of epithelial cancer | COLOTECH A/S (DK) | 2004-06-17 | — | — | US | disclosed |
| US-6703380-B2 | PREVENTION OF COLORECTAL CANCER BY ADMINISTERING A COMBINATION DOSAGE OF A CYCLOOXYGENASE COX INHIBITOR, VITAMIN D3, ANALOGUES OF VITAMIN D3, METABOLITES OF VITAMIN D3 OR A MIXTURE THEREOF AND CALCIUM. | COLOTECH A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20010049364-A1 | Prevention of cancer | RASKOV, HANS HENRIK (DK) | 2001-12-06 | — | — | US | disclosed |
| EP-0696275-B1 | VITAMIN D AMIDE DERIVATIVES | RES INST MEDICINE CHEM (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5756733-A | Vitamin D amide derivatives | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY (US) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049364-A1 | Prevention of cancer | VDR, CYP24A1, CYP2R1 | HDAC6 4746/4885HDAC3 2504/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.